NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androgen deprivation therapy, ADT ...

Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Revolution Medicines' pan-RAS (on) inhibitor daraxonrasib has delivered a big result in pancreatic cancer, with a doubling in overall survival compared to chemotherapy in the highly anticipated ...

Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the ris ...

Treatment regimen cut disease recurrence or death risk by 20% Researchers call data 'paradigm changing' J&J plans to seek expanded approvals for Erleada May 31 (Reuters) - Johnson & Johnson's (JNJ.N), ...

Melanoma, a type of skin cancer, is one of the four cancers driving Iowa’s high cancer rate. Dermatologist John Wollner ...

Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.

*Foster Sylvers, the former child star whose youthful voice and magnetic stage presence helped propel The Sylvers to national fame in the 1970s, has died. He was 64. His brother, Leon Sylvers III, ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Radical prostatectomy is potentially curative in patients with high-risk localized or locally advanced prostate cancer; however, relapse occurs within 5 years in up to 50% of patients. We conducted a ...